BioLine RX LtdNASDAQ:BLRXNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.7240
- TODAY'S CHANGE (%)0.0253 (3.6136%)
- Bid / Lots0.7003/ 12
- Ask / Lots0.7240/ 1
- Open / Previous Close0.7000 / 0.6988
- Day Range
- 52 Week Range
- Volume118,388
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BLRX |
|---|---|---|
| 09:32 ET | 2244 | 0.692 |
| 09:34 ET | 2358 | 0.6902 |
| 09:48 ET | 2766 | 0.7 |
| 09:50 ET | 300 | 0.7098 |
| 09:54 ET | 200 | 0.7099 |
| 10:03 ET | 100 | 0.7098 |
| 10:06 ET | 120 | 0.7098 |
| 10:12 ET | 200 | 0.7016 |
| 10:21 ET | 200 | 0.7057 |
| 10:32 ET | 9972 | 0.6902 |
| 10:33 ET | 1748 | 0.7 |
| 10:39 ET | 100 | 0.6994 |
| 10:46 ET | 4741 | 0.7037 |
| 10:57 ET | 100 | 0.7 |
| 11:06 ET | 316 | 0.7036 |
| 11:26 ET | 915 | 0.707303 |
| 11:31 ET | 11100 | 0.696 |
| 11:33 ET | 250 | 0.6971 |
| 11:38 ET | 200 | 0.696 |
| 11:45 ET | 425 | 0.6961 |
| 12:27 ET | 200 | 0.7069 |
| 12:39 ET | 3303 | 0.7099 |
| 12:54 ET | 1126 | 0.72 |
| 12:56 ET | 688 | 0.72 |
| 01:01 ET | 435 | 0.7303 |
| 01:10 ET | 900 | 0.73 |
| 01:12 ET | 2298 | 0.7229 |
| 01:21 ET | 2273 | 0.723899 |
| 01:26 ET | 2000 | 0.7298 |
| 01:30 ET | 1000 | 0.72989 |
| 01:37 ET | 450 | 0.7195 |
| 01:42 ET | 2608 | 0.73 |
| 01:44 ET | 4435 | 0.7299 |
| 01:46 ET | 1400 | 0.7298 |
| 01:48 ET | 2000 | 0.7298 |
| 01:51 ET | 1900 | 0.7252 |
| 01:53 ET | 5600 | 0.7203 |
| 01:55 ET | 1000 | 0.7299 |
| 01:57 ET | 1100 | 0.72 |
| 02:00 ET | 500 | 0.729892 |
| 02:02 ET | 500 | 0.7193 |
| 02:04 ET | 1500 | 0.723791 |
| 02:06 ET | 1000 | 0.7245 |
| 02:08 ET | 100 | 0.7223 |
| 02:11 ET | 200 | 0.724577 |
| 02:15 ET | 1800 | 0.726001 |
| 02:20 ET | 4478 | 0.726 |
| 02:22 ET | 100 | 0.7274 |
| 02:24 ET | 300 | 0.7246 |
| 02:26 ET | 3265 | 0.716 |
| 02:29 ET | 4900 | 0.7158 |
| 02:56 ET | 3500 | 0.7217 |
| 03:00 ET | 1108 | 0.7167 |
| 03:02 ET | 700 | 0.71665 |
| 03:03 ET | 1500 | 0.7166 |
| 03:16 ET | 2920 | 0.7116 |
| 03:27 ET | 1200 | 0.715849 |
| 03:30 ET | 3353 | 0.7217 |
| 03:32 ET | 567 | 0.7298 |
| 03:34 ET | 300 | 0.73 |
| 03:36 ET | 1757 | 0.73 |
| 03:41 ET | 100 | 0.73 |
| 03:48 ET | 300 | 0.7299 |
| 03:50 ET | 311 | 0.7196 |
| 03:56 ET | 500 | 0.724001 |
| 03:57 ET | 784 | 0.727899 |
| 03:59 ET | 1600 | 0.724 |
Jun 3, 2024
DJ BioLine RX Price Target Maintained With a $21.00/Share by HC Wainwright & Co., from 12:45PM ET on Monday Jun 03, 2024 by Dow Jones
12:45PM ET on Monday Jun 03, 2024 by Dow Jones
May 30, 2024
BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD), from 7:00AM ET on Thursday May 30, 2024 by Dow Jones
7:00AM ET on Thursday May 30, 2024 by Dow Jones
May 29, 2024
DJ BioLine RX Price Target Maintained With a $21.00/Share by HC Wainwright & Co., from 10:34AM ET on Wednesday May 29, 2024 by Dow Jones
10:34AM ET on Wednesday May 29, 2024 by Dow Jones
May 28, 2024
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates, from 7:00AM ET on Tuesday May 28, 2024 by Dow Jones
7:00AM ET on Tuesday May 28, 2024 by Dow JonesPress Release: BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates, from 7:00AM ET on Tuesday May 28, 2024 by Dow Jones
7:00AM ET on Tuesday May 28, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
BioLine RX Ltd | 58.4M | -0.9x | --- |
LAVA Therapeutics NV | 59.4M | -2.2x | --- |
Dyadic International Inc | 63.7M | -8.3x | --- |
Kronos Bio Inc | 47.5M | -0.4x | --- |
Kezar Life Sciences Inc | 50.5M | -0.5x | --- |
Cue Biopharma Inc | 79.3M | -1.5x | --- |
Company Information
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
Contact Information
- Headquarters
- Modi'in Technology Park 2 HaMa'ayan StreetMODIIN, Israel 7177871
- Phone
- ---
- Fax
- ---
Executives
- Chairman of the Board
- Aharon Schwartz
- Chief Executive Officer
- Philip Serlin
- Chief Financial Officer
- Mali Zeevi
- Vice President - Development
- Ella Sorani
- Vice President-Clinical & Medical Affairs
- Abi Vainstein-Haras
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $58.4M |
|---|---|
Revenue (TTM) | $11.7M |
Shares Outstanding | 79.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.54 |
EPS | $-0.76 |
Book Value | $0.18 |
P/E Ratio | -0.9x |
Price/Sales (TTM) | 5.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -391.76% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
